DOST study: Meals with VCO reduces COVID patient symptoms as early as day 2

Imahe via Canva
  • A study found that VCO mixed on meals has helped in the reduction of symptoms to more suspected and probable COVID patients as early as day 2
  • The DOST study was conducted among patients in Sta. Rosa, Laguna quarantine facility and hospital
  • The study lasted for 28 days and has strictly monitored the patients’ symptoms daily

VCO mixed on meals has been found out to effectively reduce COVID symptoms.

Image via Pixabay

The Department of Science and Technology revealed on December 3 the results of the joint study by the Department of Science and Technology’s Food and Nutrition Research Institute (DOST-FNRI), Philippine Council for Health Research and Development (DOST-PCHRD), Philippine Coconut Authority (DA-PCA), Department of Science and Technology (DOST) CALABARZON, City of Santa Rosa, Laguna, and the Ateneo de Manila University.

Symptoms such as cough, colds, body aches, headache, loss of taste and smell, and fever were significantly reduced and prevented COVID from worsening.

The study was facilitated at the Santa Rosa Community Quarantine Facility and at the Santa Rosa Community Hospital in Santa Rosa City, Laguna. 57 suspect and probable COVID patients joined the study that lasted 28 days. The intervention of the VCO group received meals mixed with VCO while the control group ate the usual meals without VCO.

The VCO group included 29 cases while 28 individuals belonged to the control group.

A catering service prepared the meals while registered nutritionist-dietitians added the VCO. The foods were given free at the facilities and later continued to be provided at their homes after discharge.

A VCO dosage of 0.6mL per kg/body weight was mixed to their breakfast for the first 3 days and increased to 1.2mL/kg/body weight to their breakfast and lunch on day 4 to 28.

Image via Pixabay

Results showed that 5 out of 29 patients in the VCO group had reduced symptoms as early as day 2 while the control group recorded 1 patient.

The VCO group is already symptom-free on day 18 as seen on their decreasing levels of C-Reactive Protein (CRP) while only until day 23 when the control group had no symptoms. The CRP is used to measure the severity of inflammation or infection.

This study opens the possibilities of exploring our locally-available food supplements in managing COVID. However, according to Scientist II Dr. Imelda Angeles-Agdeppa of DOST-FNRI, “more studies are still recommended to determine the effectiveness of VCO as an adjunct or supportive therapy for COVID-19 patients with other co-morbidities.”